Chloroquine phosphate is an antiparasitic medication belonging to the antimalarial class. It is available in pill form in strengths of 250 mg and 500 mg. In Hong Kong, chloroquine is a prescription-only drug regulated by the Hong Kong Department of Health. Historically it has been used to treat and prevent malaria, and it has been investigated in clinical studies for other infections, including COVID-19, although it is not approved for that indication.
Chloroquine interferes with the parasite’s ability to digest hemoglobin inside red blood cells. By accumulating in the acidic food vacuole of Plasmodium species, it raises the pH, blocking the conversion of toxic heme into harmless hemozoin. This toxic heme buildup kills the parasite.
For non-malarial investigations, chloroquine’s immunomodulatory properties are of interest. The drug can inhibit certain cellular signaling pathways (e.g., toll-like receptor activation) and reduce the release of inflammatory cytokines, which underlies its use in autoimmune conditions such as lupus. These mechanisms also prompted early research into its potential effect on viral replication, including SARS-CoV-2, though conclusive clinical benefit has not been demonstrated.
In Hong Kong, the official indication listed on the product label is the treatment and prophylaxis of malaria. Any other use, including for viral infections, falls outside the approved scope.
Early in the pandemic, small observational studies suggested that chloroquine might inhibit SARS-CoV-2 replication in vitro. Larger randomized trials, however, failed to show a clinical advantage and highlighted safety concerns, especially cardiac toxicity. Consequently, chloroquine is not approved by any regulatory agency (including the Hong Kong Department of Health) for the prevention or treatment of COVID-19.
Off-label use requires a qualified healthcare professional to weigh potential benefits against known risks, and to monitor the patient closely.
Patients should disclose all prescription medicines, over-the-counter products, supplements, and herbal preparations before starting chloroquine.
This article provides educational information about chloroquine phosphate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, chloroquine can be prescribed for malaria prevention in areas where the parasite remains sensitive to the drug. The prophylactic schedule-typically a weekly dose starting one week before travel and continuing for four weeks after departure-must be individualized by a healthcare professional based on the destination’s resistance patterns.
Early signs may include blurred vision, difficulty reading, or subtle changes in color perception. As toxicity progresses, patients may notice a “gray spot” in the central visual field. Prompt ophthalmologic assessment is essential because the condition can become irreversible.
Chloroquine crosses the placenta and is classified as pregnancy category C. Animal studies have shown adverse effects, but human data are limited. The medication may be used if the potential benefit outweighs the risk, such as in severe malaria cases, but it should be prescribed only after careful risk assessment.
Chloroquine can inhibit the CYP2D6 enzyme, which metabolizes many antidepressants (e.g., SSRIs, tricyclics). This inhibition may increase the plasma concentration of those drugs, potentially leading to heightened side effects. Monitoring and dose adjustments may be required.
Patients with known cardiac conduction disorders, a history of arrhythmias, or baseline prolonged QT interval should undergo a baseline ECG. If chloroquine is deemed necessary, the prescriber may choose the lowest effective dose, avoid concomitant QT-prolonging medications, and schedule regular cardiac monitoring.
Yes, chloroquine can potentiate insulin and oral hypoglycemic agents, leading to hypoglycemia. Diabetic patients, especially those on insulin or sulfonylureas, are at higher risk and should monitor glucose levels closely during therapy.
Large randomized clinical trials failed to demonstrate a clear benefit and identified an increased risk of cardiac toxicity, particularly QT prolongation. Regulatory agencies, including the Hong Kong Department of Health, have therefore advised against its use for COVID-19 outside of controlled research settings.
Take the missed dose as soon as remembered, unless the next scheduled dose is within a few hours. Do not double the dose to “make up” for the missed tablet; instead, continue with the regular schedule.
There are no strict dietary bans, but taking the medication with a full glass of water can reduce gastrointestinal irritation. Patients should avoid excessive alcohol consumption, which can increase liver strain.
Unwanted tablets should not be flushed down the toilet. Place them in a sealed container and bring them to a pharmacy or a collection point designated for pharmaceutical waste, following local disposal guidelines.
